{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:29:05Z","timestamp":1787009345856,"version":"build-2736575974"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Chugai Pharmaceutical Co Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the safety and effectiveness of mycophenolate mofetil (MMF) in Japanese adults with lupus nephritis (LN) in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre, prospective, post-marketing surveillance study investigated the effectiveness and safety of MMF, as induction or maintenance therapy, in LN patients. Primary endpoints were adverse drug reactions (ADRs), changes in renal function from baseline, and relapse rate (RR) after 6\u2009months in the maintenance group, estimated using the Kaplan\u2013Meier method. Complete remission (CR) and partial remission (PR) were estimated by renal measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 112 patients were enrolled in the induction group and 340 in the maintenance group. Of these 452 patients, 418 were evaluable for safety and 396 for effectiveness. Eighty-three patients (19.85%) experienced ADRs, most commonly herpes zoster (3.34%) and diarrhoea (3.11%). Serious ADRs occurring in more than three patients were cytomegalovirus infections (1.43%), acute pyelonephritis (0.71%), and herpes zoster (0.71%). One patient died from herpes zoster disseminated. CR and PR were 19.54% and 44.82%, respectively, in the induction group, and 40.62% and 66.16%, respectively, in the maintenance group. RR in the maintenance group was 0.70%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The tolerability of MMF is in line with that reported in other studies. Since the average dose of MMF was &amp;lt;1.5\u2009g\/day, research into the optimal dose for achieving effectiveness is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roab076","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T17:45:38Z","timestamp":1634751938000},"page":"746-754","source":"Crossref","is-referenced-by-count":13,"title":["Long-term safety and effectiveness of mycophenolate mofetil in adults with lupus nephritis: a real-world study in Japan"],"prefix":"10.1093","volume":"32","author":[{"given":"Tsutomu","family":"Takeuchi","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Shinjuku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., Nihonbashi Mitsui Tower , Ch\u016b\u014d, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd., Nihonbashi Mitsui Tower , Ch\u016b\u014d, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"2022070111364608200_R1","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Disease Prim"},{"key":"2022070111364608200_R2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology"},{"key":"2022070111364608200_R3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022070111364608200_R4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/acr.20683","article-title":"Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality","volume":"64","author":"Jakes","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2022070111364608200_R5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203307080225","article-title":"Ethnic, clinical and immunological factors in systemic lupus erythematosus and the development of lupus nephritis: results from a multi-ethnic New Zealand cohort","volume":"16","author":"Burling","year":"2007","journal-title":"Lupus"},{"key":"2022070111364608200_R6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/nep.12136","article-title":"Overview of lupus nephritis management guidelines and perspective from Asia","volume":"19","author":"Mok","year":"2014","journal-title":"Nephrology"},{"key":"2022070111364608200_R7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022070111364608200_R8","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.160041","article-title":"Treatments for lupus nephritis: a systematic review and network metaanalysis","volume":"43","author":"Singh","year":"2016","journal-title":"J Rheumatol"},{"key":"2022070111364608200_R9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022070111364608200_R10","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"2022070111364608200_R11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"2022070111364608200_R12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2022070111364608200_R13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3999\/jscpt.45.59","article-title":"Analysis of the situation of new indication approvals based on publicly know applications and consideration of measures for its effective utilization","volume":"45","author":"Furukawa","year":"2014","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"2022070111364608200_R14","first-page":"858","article-title":"A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan","volume":"25","author":"Hara","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2022070111364608200_R15","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3109\/14397595.2015.1031444","article-title":"Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan","volume":"25","author":"Yasuda","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2022070111364608200_R16","article-title":"Ordinance related to standards for conducting post-marketing surveys and studies on drugs","volume-title":"Notification No. 171","author":"Ministry of Health Labor and Welfare","year":"2004"},{"key":"2022070111364608200_R17","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2022070111364608200_R18","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1055\/s-0038-1649901","article-title":"Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH","volume":"74","author":"Brandt","year":"1995","journal-title":"Thromb Haemost"},{"key":"2022070111364608200_R19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1055\/s-0038-1648143","article-title":"Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants","volume":"65","author":"Exner","year":"1991","journal-title":"Thromb Haemost"},{"key":"2022070111364608200_R20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/ajcp\/94.4.476","article-title":"Special report. The second international anti-cardiolipin standardization workshop\/the Kingston anti-phospholipid antibody study (KAPS) group","volume":"94","author":"Harris","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"2022070111364608200_R21","first-page":"215","article-title":"Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986","volume":"68","author":"Harris","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"2022070111364608200_R22","first-page":"1835","article-title":"Systemic lupus erythematosus and the antiphospholipid syndrome: reflections about the relevance of ARA criteria","volume":"19","author":"Piette","year":"1992","journal-title":"J Rheumatol"},{"key":"2022070111364608200_R23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/096120339400300416","article-title":"Antiphospholipid syndrome within systemic lupus erythematosus","volume":"3","author":"Alarcon-Segovia","year":"1994","journal-title":"Lupus"},{"key":"2022070111364608200_R24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00005792-198911000-00004","article-title":"The \u201cprimary\u201d antiphospholipid syndrome: major clinical and serological features","volume":"68","author":"Asherson","year":"1989","journal-title":"Medicine"},{"key":"2022070111364608200_R25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00005792-198911000-00003","article-title":"Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients","volume":"68","author":"Alarcon-Segovia","year":"1989","journal-title":"Medicine"},{"key":"2022070111364608200_R26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(83)91267-9","article-title":"Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus","volume":"2","author":"Harris","year":"1983","journal-title":"Lancet"},{"key":"2022070111364608200_R27","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"2022070111364608200_R28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.ki.5002118","article-title":"The ISN\/RPS 2003 classification of lupus nephritis: an assessment at 3 years","volume":"71","author":"Markowitz","year":"2007","journal-title":"Kidney Int"},{"key":"2022070111364608200_R29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N Engl J Med"},{"key":"2022070111364608200_R30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10157-018-1590-2","article-title":"Investigation on the benefits of mycophenolate mofetil and therapeutic drug monitoring in the treatment of Japanese patients with lupus nephritis","volume":"22","author":"Katsuno","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2022070111364608200_R31","first-page":"139","article-title":"Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"Cattran","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2022070111364608200_R32","article-title":"Efficacy of high-dose mycophenolate mofetil in multitarget therapy for lupus nephritis: two consecutive case reports","volume":"12","author":"Furuto","year":"2020","journal-title":"Cureus"},{"key":"2022070111364608200_R33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/ndt\/gfy026","article-title":"The utility of trough mycophenolic acid levels for the management of lupus nephritis","volume":"34","author":"Pourafshar","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2022070111364608200_R34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/ndt\/gfy284","article-title":"Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis","volume":"35","author":"Yap","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2022070111364608200_R35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5414\/CN109450","article-title":"Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis","volume":"91","author":"Deng","year":"2019","journal-title":"Clin Nephrol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roab076\/41746683\/roab076.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/4\/746\/44367207\/roab076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/4\/746\/44367207\/roab076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T07:37:57Z","timestamp":1656661077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/4\/746\/6375228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,10,18]]},"published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roab076","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2021,10,18]]}}}